EHealth technologies in inflammatory bowel disease: A systematic review

Journal of Crohn's and Colitis

Volumn 10, Issue 9, 2016, Pages 1103-1121

  Jackson, Belinda D ^a,b   Gray, Kathleen ^c   Knowlesd, Simon R ^b,d,e,f   De Cruz, Peter ^a,b  

^a AUSTIN HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

EHealth; Inflammatory bowel disease; Remote consultation; Self management; Telemedicine

Indexed keywords

ABSENTEEISM; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; E-MAIL; FEASIBILITY STUDY; HUMAN; INFLAMMATORY BOWEL DISEASE; KNOWLEDGE; MEDICAL TECHNOLOGY; MOBILE APPLICATION; MOBILE PHONE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PATIENT-REPORTED OUTCOME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRODUCTIVITY; PUBLICATION; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SELF CARE; SHORT COURSE THERAPY; SOCIAL MEDIA; SYMPTOM; SYSTEMATIC REVIEW; TELEHEALTH; TELEMEDICINE; CANADA; COST BENEFIT ANALYSIS; ECONOMICS; EUROPE; HEALTH CARE QUALITY; INFLAMMATORY BOWEL DISEASES; INTERNET; OUTCOME ASSESSMENT; PROCEDURES; STANDARDS; UNITED STATES;

CANADA; COST-BENEFIT ANALYSIS; EUROPE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERNET; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY ASSURANCE, HEALTH CARE; SELF CARE; TELEMEDICINE; UNITED STATES;

EID: 85012247295     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw059     Document Type: Review

References (107)

1. Jewell DP, Satsangi J, Lobo A, et al. Infliximab use in Crohn's disease: Impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005;17:1047-52.
2. Kassam Z, Belga S, Roifman I, et al. Inflammatory bowel disease cause-specific mortality: A primer for clinicians. Inflamm Bowel Dis 2014;20:2483-92.
3. IBD Standards Group. Standards for the Healthcare of People who have Inflammatory Bowel Disease (IBD). 2013 update. http://www.ibdstandards. org.uk/. Accessed April 6, 2016.
4. Huang VW, Reich KM, Fedorak RN. Distance management of inflammatory bowel disease: Systematic review and meta-analysis. World J Gastroenterol 2014;20:829-42.
5. Walker JR, Ediger JP, Graff LA, et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol 2008;103:1989-97.
6. Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol 2013;11:43-8.
7. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54 e42; quiz e30.
8. van Langenberg DR, Simon SB, Holtmann GJ, Andrews JM. The burden of inpatient costs in inflammatory bowel disease and opportunities to optimize care: A single metropolitan Australian center experience. J Crohns Colitis 2010;4:413-21.
9. Gröne O, Garcia-Barbero M, WHO European Office for Integrated Health Care Services. Integrated care: a position paper of the WHO European Office for Integrated Health Care Services. Int J Integr Care 2001;1:e21.
10. Mikocka-Walus AA, Turnbull D, Holtmann G, Andrews JM. An integrated model of care for inflammatory bowel disease sufferers in Australia: Development and the effects of its implementation. Inflamm Bowel Dis 2012;18:1573-81.
11. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140:1785-94.
12. Kiss LS, Lakatos PL. Natural history of ulcerative colitis: current knowledge. Curr Drug Targets 2011;12:1390-5.
13. PriceWaterhouseCoopers. Improving Inflammatory Bowel Disease care across Australia. Crohn's & Colitis Australia; 2013.
14. Ramsden VR, McKay S, Bighead S, et al. Participatory health research: Celebrating smoke-free homes. Can Fam Physician 2013;59:1014-5.
15. Parchman ML, Zeber JE, Palmer RF. Participatory decision making, patient activation, medication adherence, and intermediate clinical outcomes in type 2 diabetes: a STARNet study. Ann Fam Med 2010;8:410-7.
16. Frydman G. A patient-centric definition of participatory medicine. Eepatients. net 2013. http://e-patients.net/archives/2010/04/a-patient-centricdefinition-of-participatory-medicine.html[A8]. Accessed March 11, 2016.
17. Participatory medicine. 2015. http://www.epatientdave.com/category/participatory-medicine/. Accessed March 11, 2016.
18. Frydman G. Patient-driven research: Rich opportunities and real risks. J Participat Med 2009;1:e12.
19. Gallant LM, Irizarry C, Boone G, Kreps GL. Promoting participatory medicine with social media: New media applications on hospital websites that enhance health education and e-patients' voices. J Participat Med 2011;3:e49.
20. Eysenbach G, CONSORT-EHEALTH Group. CONSORT-EHEALTH: Improving and standardizing evaluation reports of Web-based and mobile health interventions. J Med Internet Res 2011;13:e126.
21. Eysenbach G. What is e-health? J Med Internet Res 2001;3:E20.
22. Barlow C, Cooke D, Mulligan K, Beck E, Newman S. A critical review of self-management and educational interventions in inflammatory bowel disease. Gastroenterol Nurs 2010;33:11-8.
23. Cross RK, Cheevers N, Rustgi A, Langenberg P, Finkelstein J. Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflamm Bowel Dis 2012;18:1018-25.
24. Elkjaer M, Shuhaibar M, Burisch J, et al. E-health empowers patients with ulcerative colitis: A randomised controlled trial of the web-guided 'Constant-care' approach. Gut 2010;59:1652-61.
25. Hommel KA, Hente E, Herzer M, Ingerski LM, Denson LA. Telehealth behavioral treatment for medication nonadherence: a pilot and feasibility study. Eur J Gastroenterol Hepatol 2013;25:469-73.
26. Krier M, Kaltenbach T, McQuaid K, Soetikno R. Potential use of telemedicine to provide outpatient care for inflammatory bowel disease. Am J Gastroenterol 2011;106:2063-7.
27. Pedersen N, Elkjaer M, Duricova D, et al. eHealth: Individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn's disease. Aliment Pharmacol Ther 2012;36:840-9.
28. Pedersen N, Thielsen P, Martinsen L, et al. eHealth: Individualization of mesalazine treatment through a self-managed web-based solution in mildto-moderate ulcerative colitis. Inflamm Bowel Dis 2014;20:2276-85.
29. Australian Bureau of Statistics. Household Use of Information Technology, Australia. 2014-15 http://www.abs.gov.au/. Accessed March 11, 2016.
30. Brooks RG, Menachemi N. Physicians' use of email with patients: Factors influencing electronic communication and adherence to best practices. J Med Internet Res 2006;8:e2.
31. Gaster B, Knight CL, DeWitt DE, Sheffield JV, Assefi NP, Buchwald D. Physicians' use of and attitudes toward electronic mail for patient communication. J Gen Intern Med 2003;18:385-9.
32. Jones LM, Veinot TC, Pressler SJ, et al. Internet health information seeking (IHIS): An integrative review of the literature. West J Nurs Res 2014;36:1376-7.
33. Jackson B, Con D, De Cruz PP. Patients' attitudes to eHealth as a potential solution for inflammatory bowel disease self-management. Unpublished data; 2015.
34. Panes J, de Lacy AM, Sans M, Soriano A, Pique JM. [Frequent Internet use among Catalan patients with inflammatory bowel disease]. Gastroenterol Hepatol 2002;25:306-9.
35. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions: Version 5.1.0; [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook. org. Accessed March 11, 2016.
36. EPHPP. Quality assessment tool for qualitative studies. 2009. Effective Public Health Practice Project. http://www.ephpp.ca/tools.html. Accessed March 11, 2016.
37. Knowles SR, Mikocka-Walus A. Utilization and efficacy of internet-based eHealth technology in gastroenterology: A systematic review. Scand J Gastroenterol 2014;49:387-408.
38. Calvert CR, Lai S, Stansfield C, McLaughlin J, Robinson A. OC-082 The development of a web-based system to enhance care in inflammatory bowel disease. Gut 2013;62:A35-A6.
39. Odze RD, Goldblum J, Noffsinger A, Alsaigh N, Rybicki LA, Fogt F. Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod Pathol 2002;15:379-86.
40. McCombie A, Gearry R, Andrews J, Mulder R, Mikocka-Walus A. Does computerized cognitive behavioral therapy help people with inflammatory bowel disease? A randomized controlled trial. Inflamm Bowel Dis 2016;22:171-81.
41. Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12:1246-56 e6.
42. Merolli M, Gray K, Martin-Sanchez F. Developing a framework to generate evidence of health outcomes from social media use in chronic disease management. Med 2 0 2013;2:e3.
43. Wright EK, De Cruz PP, Kamm MA, et al. Faecal calprotectin is superior to faecal lactoferrin and S100A12. J Crohns Colitis 2014;8 (Suppl 1):S46. Abstract DOP064.
44. Schipper H. Guidelines and caveats for quality of life measurement in clinical practice and research. Oncology 1990;4:51-7; discussion 70.
45. McCormick M, Reed-Knight B, Lewis JD, Gold BD, Blount RL. Coping skills for reducing pain and somatic symptoms in adolescents with IBD. Inflamm Bowel Dis 2010;16:2148-57.
46. Tinsley A, Macklin EA, Korzenik JR, Sands BE. Validation of the functional assessment of chronic illness therapy-fatigue (FACIT-F) in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011;34:1328-36.
47. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012;61:241-7.
48. Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient Activation Measure (PAM): Conceptualizing and measuring activation in patients and consumers. Health Serv Res 2004;39:1005-26.
49. Breitscheidel L, Stamenitis S. Using patient-reported outcome assessments in clinical practice and their importance in risk management. J Med Econ 2009;12:180-1.
50. Castro HK, Cross RK, Finkelstein J. Using a Home Automated Telemanagement (HAT) system: Experiences and perceptions of patients with inflammatory bowel disease. AMIA Annu Symp Proc 2006:872.
51. Finkelstein J, O'Connor G, Friedmann RH. Development and implementation of the home asthma telemonitoring (HAT) system to facilitate asthma self-care. Stud Health Technol Inform 2001;84:810-4.
52. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67-74.
53. Wardle RA, Mayberry JF. Patient knowledge in inflammatory bowel disease: the Crohn's and Colitis Knowledge Score. Eur J Gastroenterol Hepatol 2014;26:1-5.
54. Cross RK, Arora M, Finkelstein J. Acceptance of telemanagement is high in patients with inflammatory bowel disease. J Clinical Gastroenterol 2006;40:200-8.
55. Feagan BG, Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol 2000;95:1955-60.
56. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: A single centre retrospective study. Gut 2004;53:1471-8.
57. Longobardi T, Bernstein CN. Health care resource utilization in inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:731-43.
58. van der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut 2014;63:72-9.
59. Eysenbach G. The law of attrition. J Med Internet Res 2005;7:e11.
60. Andersson G, Cuijpers P. Pros and cons of online cognitive-behavioural therapy. Br J Psychiatry 2008;193:270-1.
61. Richards D, Richardson T. Computer-based psychological treatments for depression: A systematic review and meta-analysis. Clin Psychol Rev 2012;32:329-42.
62. ISD Scotland. SMR Datasets, Virtual Clinic. 2015. http://www.ndc.scot. nhs.uk/Data-Dictionary/SMR-Datasets/SMR00-Outpatient-Attendance/Virtual-Clinic/. Accessed December 24, 2015.
63. Johnson M, Lithgo K, Price T. OC-080 Ibd-Sshamp (Supported, Self help and Management Programme); UK's first Internet based Remote Management System for Managing Stable IBD. Gut 2013;62:A34-5.
64. Hunter J, Claridge A, James S, et al. Improving outpatient services: the Southampton IBD virtual clinic. Postgrad Med J 2012;88:487-91.
65. Lichtenstein GR, Rubin D. Gastroenterology Virtual Clinic. 2014.
66. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010;59:666-89.
67. Strehle EM, Shabde N. One hundred years of telemedicine: does this new technology have a place in paediatrics? Arch Dis Child 2006;91:956-9.
68. Association TAT. 2012.
69. Regueiro MD, Greer JB, Binion DG, et al. The inflammatory bowel disease live interinstitutional and interdisciplinary videoconference education (IBD LIVE) series. Inflamm Bowel Dis 2014;20:1687-95.
70. Con D, De Cruz P. Mobile phone apps for inflammatory bowel disease self-management: A systematic assessment of content and tools. JMIR Mhealth Uhealth 2016;4:e13.
71. Cross RK, Jambaulikar G, Langenberg P, et al. TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Design and implementation of randomized clinical trial. Contemp Clin Trials 2015;42:132-44.
72. Atreja A, Khan S, Rogers JD, et al. Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial. JMIR Res Protoc 2015;4:e23.
73. Vinding KK, Elsberg H, Thorkilgaard T, et al. Fecal calprotectin measured by patients at home using smartphones-a new clinical tool in monitoring patients with inflammatory bowel disease. Inflamm Bowel Dis 2016;22:336-44.
74. Choi JM, van Deen WK, Nguyen L, et al. The value of social media in inflammatory bowel diseases. European Crohn's and Colitis Organisation Abstracts 2014. P327.
75. Knowles SR, Mikocka-Walus A. Psychological Aspects of Inflammatory Bowel Disease: A biopsychosocial approach. 2014:XVIII-XXIV.
76. Plener I, Hayward A, Saibil F. E-mail communication in the management of gastroenterology patients: A review. Can J Gastroenterol Hepatol 2014;28:161-5.
77. Stiles-Shields C, Keefer L. Web-based interventions for ulcerative colitis and Crohn's disease: systematic review and future directions. Clin Exp Gastroenterol 2015;8:149-57.
78. Fortinsky KJ, Fournier MR, Benchimol EI. Internet and electronic resources for inflammatory bowel disease: A primer for providers and patients. Inflamm Bowel Dis 2012;18:1156-63.
79. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: Current management. J Crohns Colitis 2012;6:991-1030.
80. Vester-Andersen MK, Prosberg MV, Jess T, et al. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol 2014;109:705-14.
81. Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: A Quebec claims database study. Inflamm Bowel Dis 2015;21:1847-53.
82. Aberra FN, Lichtenstein GR. Review article: monitoring of immunomodulators in inflammatory bowel disease. Aliment Pharmacol Ther 2005;21:307-19.
83. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015;110:1324-38.
84. Iacucci M, Ghosh S. Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. Therap Adv Gastroenterol 2011;4:129-43.
85. Eller LS, Rivero-Mendez M, Voss J, et al. Depressive symptoms, selfesteem, HIV symptom management self-efficacy and self-compassion in people living with HIV. AIDS Care 2014;26:795-803.
86. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218-24.
87. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011;140:1817-26 e2.
88. Elbert NJ, van Os-Medendorp H, van Renselaar W, et al. Effectiveness and cost-effectiveness of ehealth interventions in somatic diseases: a systematic review of systematic reviews and meta-analyses. J Med Internet Res 2014;16:e110.
89. Palen TE, Ross C, Powers JD, Xu S. Association of online patient access to clinicians and medical records with use of clinical services. JAMA 2012;308:2012-9.
90. Kelstrup AM, Juillerat P, Korzenik J. The accuracy of self-reported medical history: A preliminary analysis of the promise of internet-based research in Inflammatory Bowel Diseases. J Crohns Colitis 2014;8:349-56.
91. Howie JG, Heaney DJ, Maxwell M, Walker JJ, Freeman GK, Rai H. Quality at general practice consultations: cross sectional survey. BMJ 1999;319:738-43.
92. Barlow J, Wright C, Sheasby J, Turner A, Hainsworth J. Self-management approaches for people with chronic conditions: A review. Patient Educ Couns 2002;48:177-87.
93. Kennedy A, Gask L, Rogers A. Training professionals to engage with and promote self-management. Health Educ Res 2005;20:567-78.
94. Coulter A. Partnerships with patients: The pros and cons of shared clinical decision-making. J Health Serv Res Policy 1997;2:112-21.
95. Clark NM, Gong M. Management of chronic disease by practitioners and patients: Are we teaching the wrong things? BMJ 2000;320:572-5.
96. Panes J, O'Connor M, Peyrin-Biroulet L, Irving P, Petersson J, Colombel JF. Improving quality of care in inflammatory bowel disease: What changes can be made today? J Crohns Colitis 2014;8:919-26.
97. Murray E. Web-based interventions for behavior change and self-management: potential, pitfalls, and progress. Medicine 20 2012;1:e3.
98. Makai P, Melis RJ, Olde-Rikkert MG. Technical difficulties and evaluating e-health interventions. JAMA Intern Med 2014;174:304-5.
99. Bennett GG, Glasgow RE. The delivery of public health interventions via the Internet: actualizing their potential. Annu Rev Public Health 2009;30:273-92.
100. Koppel R, Metlay JP, Cohen A, et al. Role of computerized physician order entry systems in facilitating medication errors. JAMA 2005;293:1197-203.
101. Glasgow RE. eHealth evaluation and dissemination research. Am J Prev Med 2007;32:S119-26.
102. Anderson R. New MRC guidance on evaluating complex interventions. BMJ 2008;337:a1937.
103. Pagliari C. Design and evaluation in eHealth: Challenges and implications for an interdisciplinary field. J Med Internet Res 2007;9:e15.
104. van Limburg M, Wentzel J, Sanderman R, van Gemert-Pijnen L. Business Modeling to Implement an eHealth Portal for Infection Control: A Reflection on Co-Creation With Stakeholders. JMIR Res Protoc 2015;4:e104.
105. Agboola S, Hale TM, Masters C, Kvedar J, Jethwani K. "Real-world" practical evaluation strategies: a review of telehealth evaluation. JMIR Res Protoc 2014;3:e75.
106. Rigby M. Impact of telemedicine must be defined in developing countries. BMJ 2002;324:47-8.
107. Prainsack B. The powers of participatory medicine. PLoS Biol 2014;12:e1001837.